Drug Profile


Alternative Names: Acetorphan; Hidrasec; Racemic acetorphan; Tiorfan; Tiorfast; Tiorfix

Latest Information Update: 21 Jan 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bioprojet
  • Developer Abbott Laboratories; Bago; Bioprojet; Ferrer; GlaxoSmithKline; Leti; Nordic Drugs; Takeda
  • Class Antidiarrhoeals; Antisecretories; Benzyl compounds; Esters; Small molecules; Sulfhydryl compounds; Sulfur amino acids
  • Mechanism of Action Neprilysin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Diarrhoea

Most Recent Events

  • 01 Nov 2013 Bioprojet completes a phase I trial in Diarrhoea (in volunteers) in France (NCT01948011)
  • 30 Sep 2013 Phase-I clinical trials in Diarrhoea (in volunteers) in France (PO, suspension)
  • 16 Jul 2002 A study has been added to the adverse events and Digestive System Disorders pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top